Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

SHAREHOLDER ALERT: Robbins LLP Announces That BELLUS Health Inc. (BLU) is Being Sued for Misleading Shareholders

March 30, 2021 GMT

SAN DIEGO & LAVAL, Quebec--(BUSINESS WIRE)--Mar 30, 2021--

Shareholder rights law firm Robbins LLP announces that a purchaser of BELLUS Health Inc. (NASDAQ: BLU) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between September 5, 2019 and July 5, 2020. BELLUS is a clinical-stage biopharmaceutical company whose lead product is BLU-5937, which is being developed for the treatment of chronic cough and other afferent hypersensitization-related disorders.


If you suffered a loss due to BELLUS Health Inc.’s misconduct, click here.

BELLUS Health Inc. (BLU) Misled Investors About its Lead Product Candidate

According to the complaint, BELLUS common stock began trading on September 5, 2019. In its Registration Statement, BELLUS touted the efficacy of BLU-5937 and its superiority over Merck & Co’s drug currently in development for chronic cough, gefapizant. Specifically, BELLUS noted that gefapizant reportedly caused taste alternation and/or loss in up to 80% of patients, while BLU-5937 caused temporary alteration in just 5% of patients and taste loss in no patients. The Registration Statement included information about the clinical development of gefapizant as support for the expected efficacy and safety of BLU-5937. Though the Registration Statement noted other similar products in various stages of development, it touted how BLU-5937 was different and better based on its high selectivity. BELLUS repeated these statements and sentiments throughout the class period. However, the Company failed to disclose that high selectivity contributed to the drug being potentially less effective and likely not to be able to meet the primary endpoint of its Phase 2 trial.

On July 6, 2020, BELLUS revealed that the trial “did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency at any dose tested.” Only ”[a] clinically meaningful and highly statistically significant placebo-adjusted reduction in cough frequency was achieved in a specified sub-group of high cough count patients (all patients at or above the baseline median average of 32.4 coughs per hour),” so the Company intended to move “forward into an adaptive Phase 2b trial enriched for higher cough count patients. We expect to begin this trial in the fourth quarter of 2020.” On this news, BELLUS’ stock price plummeted over 75% from a class period high of $12.02 on June 29, 2020, to close at $2.97 on July 8, 2020.


If you purchased shares of BELLUS Health Inc. (BLU) between September 5, 2019 and July 5, 2020, you have until May 17, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against BELLUS Health Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210330005961/en/

CONTACT: Lauren Levi

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122


(800) 350-6003





Copyright Business Wire 2021.

PUB: 03/30/2021 02:45 PM/DISC: 03/30/2021 02:45 PM